Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
12.29
+0.48 (4.06%)
At close: Mar 19, 2026, 4:00 PM EDT
12.43
+0.14 (1.16%)
After-hours: Mar 19, 2026, 6:58 PM EDT
Generate Biomedicines Revenue
In the year 2025, Generate Biomedicines had annual revenue of $31.89M with 55.89% growth.
Revenue (ttm)
$31.89M
Revenue Growth
+55.89%
P/S Ratio
49.11
Revenue / Employee
$102,221
Employees
312
Market Cap
1.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.89M | 11.43M | 55.89% |
| Dec 31, 2024 | 20.46M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGENB News
- 19 days ago - U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market - Seeking Alpha
- 20 days ago - Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - Reuters
- 21 days ago - Drug developer Generate Biomedicines raises $400 million in US IPO - Reuters
- 21 days ago - Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering - PRNewsWire
- 24 days ago - Generate Biomedicines aims to raise $425 million in US IPO - Reuters
- 26 days ago - U.S. IPO Weekly Recap: IPO Market Stays Fairly Quiet During The Short Holiday Week - Seeking Alpha
- 5 weeks ago - U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years - Seeking Alpha
- 5 weeks ago - Generate Biomedicines Begins IPO Push With Major Collaboration Deals - Seeking Alpha